ARS Pharmaceuticals, Inc.
SPRYHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. At a $558.9M market cap, ARS Pharmaceuticals, Inc. ranks as a small-cap company within healthcare. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Market Cap
$558.9M
Beta
1.00
P/E (TTM)
—
P/E (Fwd)
-6.31
EPS (TTM)
$-2.18
EPS (Fwd)
$-0.89
ROE
-210.3%
ROA
-48.0%
Cash
$143.8M
Total Debt
$171.6M
Free CF
-$117.7M
52W Change
-47.5%
Annual Financials
Cash vs Debt
Where SPRY stands vs its 150-day and 200-day moving averages
As of the August 12, 2026 close, SPRY finished 30.73% below its 150-day moving average ($8.59) and 32.62% below its 200-day moving average ($8.83). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SPRY overbought or oversold?
At the August 12, 2026 close, SPRY's RSI(14) was 48.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, SPRY has $143.8M in cash with $171.6M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$117.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -210.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $1.3M to $84.3M.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ARS Pharmaceuticals, Inc.'s trajectory.